Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mahmoud Altawil

Cardiovascular Disease Orlando, FL Medical Doctor

NPI 1104264308 CMS profile 4220221

258 S Chickasaw Trl Ste 203, Ste 203, Orlando, FL 32825

Open in the dashboard

General payments

$61,241

333 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mahmoud Altawil of Orlando, FL is reported in the CMS Open Payments database as having received $61,241 across 333 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,301 86
2024 General $17,184 61
2023 General $5,412 44
2022 General $9,486 61
2021 General $3,926 36
2020 General $2,969 18
2019 General $5,964 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mahmoud Altawil
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Mahmoud Altawil were reported at $16,301. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Mahmoud Altawil Cardiovascular Disease median Middle half National median
2019 $5,964 $450 $127–$1,392 $163
2020 $2,969 $242 $77–$751 $114
2021 $3,926 $335 $101–$1,037 $132
2022 $9,486 $395 $121–$1,211 $149
2023 $5,412 $443 $136–$1,283 $160
2024 $17,184 $450 $136–$1,323 $164
2025 $16,301 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biotronik Inc. $13,432 53 payments
  2. Boston Scientific Corporation $12,723 58 payments
  3. Medtronic, Inc. $9,529 86 payments
  4. Medical Device Business Services, Inc. $9,062 6 payments
  5. Biosense Webster, Inc. $7,263 32 payments
  6. Abbott Laboratories $3,838 43 payments
  7. Medtronic Vascular, Inc. $3,157 25 payments
  8. Atricure, Inc. $859 7 payments
  9. AltaThera Pharmaceuticals LLC $600 1 payment
  10. Impulse Dynamics (USA) Inc. $509 7 payments
  11. Other $269 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $28,322 92 payments
  2. Food and Beverage $16,914 227 payments
  3. Consulting Fee $14,775 9 payments
  4. Grant $901 1 payment
  5. Education $329 4 payments
Products named General payments · program years 2019–2025
  1. Carto 3 $16,313 37 payments
  2. Micra $3,693 28 payments
  3. General Therapies $3,353 12 payments
  4. Solia $2,602 17 payments
  5. FARAPULSE $2,283 7 payments
  6. Edora $1,733 13 payments
  7. Acticor $1,733 13 payments
  8. BioMonitor $1,709 14 payments
  9. General - Therapies $1,458 5 payments
  10. Rivacor $1,446 12 payments
  11. Other $13,290 140 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

292

Median for Cardiology: 2,533

Drug cost

$62,477

Median for Cardiology: $485,213

Branded share of claims

55.1%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 54 $39,492
Multaq Dronedarone Hcl Brand 11 $10,062
Xarelto Rivaroxaban Brand 15 $9,888
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 30 $825
Flecainide Acetate Generic 12 $614
Metoprolol Succinate Generic 46 $543
Amiodarone Hcl Generic 26 $491
Dilt-Xr Diltiazem Hcl Brand 22 $216
Tiadylt Er Diltiazem Hcl Brand 16 $143
Carvedilol Generic 18 $116

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$101,675

Medicare's payments for the services billed

Medicare patients

295

Average age 76

Services billed

1,369

144 women, 151 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 65%
Atrial fibrillation 61%
Heart failure 56%
Diabetes 51%
Chronic kidney disease 51%
Arthritis 48%
Depression 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sotalol Hydrochloride
  • AltaThera Pharmaceuticals LLC $600
$600 — —
VYNDAQEL
  • PFIZER INC. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

333 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record